A Phase I/IIa Study of JAB-23E73 in Patients With Advanced Solid Tumors Harboring KRAS Gene Alteration

NCT06959615 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

RECRUITING

Status

334

Enrollment

INDUSTRY

Sponsor class

Conditions

Advanced Solid Tumor

Interventions

DRUG: JAB-23E73
DRUG: JAB-23E73

Sponsor

Jacobio Pharmaceuticals Co., Ltd.